On Tuesday, Sirius XM Holdings Inc.(NASDAQ:SIRI)’s shares inclined 0.13% to $3.85.
SiriusXM declared its exclusive programming in celebration of Hispanic Heritage Month.
Superstar Latin rock band Mana will take over SiriusXM’s Caliente channel to host Mana Radio, featuring classic Mana songs, in addition to songs from their most recent album, Cama Incendiada. The weekend take-over is hosted by band members Fher Olvera, Juan Calleros, Alex Gonzalez, and Sergio Vallin talking about their music and influences and will comprise a rebroadcast of “SiriusXM’s Town Hall with Mana.”
Mana’s takeover will be broadcast starting on Saturday, September 19 at 9:00 am ET and will air through Sunday, September 20 via satellite on Caliente, Sirius channel 69, XM channel 158 and through the SiriusXM App on smartphones and other connected devices, in addition to online at siriusxm.com.
Sirius XM Holdings Inc., through its auxiliaries, provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, counting various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic reports for 22 metropolitan markets.
QUALCOMM, Inc.(NASDAQ:QCOM)’s shares dropped -0.83% to $53.94.
Semiconductor Manufacturing International Corp. (SMIC), China Integrated Circuit Industry Investment Fund Co., Ltd., (CICIIF), and a partner of Qualcomm Incorporated have declared the signing of a non-legally binding term sheet regarding contemplated investment of $280 million dollars in the aggregate in SJ Semiconductor Corp. (SJsemi). If the contemplated investment is accomplished, the funds raised by SJsemi will be put towards expediting the establishment of China’s first 12″ bumping production line, which is predictable to expand the scale of production, improve its advanced manufacturing capabilities and improve China’s overall chip manufacturing ecosystem.
Located in Jiangyin, Jiangsu province, SJsemi was founded in August 2014 through a joint venture between SMIC and Jiangsu Changjiang Electronics Technology Co., Ltd. (JCET). SJsemi will serve as the world’s first pure play Middle-End-Of-Line (MEOL) entity that focuses on advanced bumping production. Complementing nearby advanced back-end assembly infrastructure, SJsemi will be an important key to forming a local integrated circuit (IC) ecosystem, providing a convenient one-stop service to supply high quality and efficient chips for local and international customers, in addition to assist strengthen their global competiveness. Within one year of its establishment, SJsemi has already successfully commissioned its production process and passed production qualification and is predictable to go into mass production at the starting of 2016.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States.
At the end of Tuesday’s trade, Bristol-Myers Squibb Co (NYSE:BMY)‘s shares dipped -1.04% to $62.07.
Bristol-Myers Squibb Company (BMY) declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of advanced or metastatic renal cell carcinoma (RCC). The Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines with early signals of potential clinical benefit in serious diseases to assist ensure patients have access to new therapies as soon as possible.
This designation is based on results of CheckMate -025, a Phase 3 study that evaluated the survival of patients with formerly treated advanced or metastatic clear-cell RCC as compared to everolimus, a current standard of care for patients with formerly treated kidney cancer. The trial was stopped early in July 2015 because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint of overall survival, demonstrating superior overall survival in patients receiving Opdivo contrast to the control arm. Bristol-Myers Squibb will be presenting further data from this study at the forthcoming 2015 European Cancer Congress (ECC), and looks forward to submitting these data to regulatory authorities this year.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Quantum Corp(NYSE:QTM), ended its Tuesday’s trading session with -5.74% loss, and closed at $0.801.
Quantum International Income Corp. (QTM), declared that it has retained LodeRock Advisors Inc. for planned investor relations and capital markets communications services
Under the terms of the agreement, Quantum International will pay LodeRock a monthly fee of CAD $10,000 for select planned communication services. Neither LodeRock, nor any of its executives have an ownership interest, directly or indirectly, in Quantum International or its securities, and Quantum International has not granted LodeRock or its executives any right to acquire any such interests.
Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific. Its scale-out storage portfolio comprises StorNext software, appliances and full systems called StorNext Pro Solutions, in addition to Lattus extended online storage and Q-Cloud Archive services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
